AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021
November 18, 2020 08:35 ET
|
AZTherapies, Inc.
Last Patient/Last Visit completed on November 13th enabling full clinical database lock BOSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical...
AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors
October 01, 2020 08:46 ET
|
AZTherapies, Inc.
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the appointment of Marc de...
AZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing
September 29, 2020 08:46 ET
|
AZTherapies, Inc.
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6...
AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)
September 09, 2020 08:34 ET
|
AZTherapies, Inc.
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the dosing of the first...
AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board
August 11, 2020 08:35 ET
|
AZTherapies, Inc.
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the expansion of its...
AZTherapies Strengthens Board of Directors & Business Advisory Board with New Appointments
July 22, 2020 08:35 ET
|
AZTherapies, Inc.
Noah Gottdiener of Duff & Phelps and Thierry Porté of J.C. Flowers & Co. join BOD Retired Eli Lilly executive Joseph B. Kelley joins Business Advisory Board BOSTON, July 22, 2020 (GLOBE...
AZTherapies to Present at 22nd Annual BIO CEO & Investor Conference
February 04, 2020 08:47 ET
|
AZTherapies, Inc.
BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced its participation in the 22nd Annual BIO CEO...
AZTherapies Announces Publication of Data Supporting the Targeting of Neuroinflammation in the Treatment of ALS in Scientific Reports
December 03, 2019 08:32 ET
|
AZTherapies, Inc.
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS Company expects to advance its re-engineered inhaled cromolyn candidate AZT-101...
AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
November 06, 2019 16:05 ET
|
AZTherapies, Inc.
BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that Ernest D. Penachio has joined the...
AZTherapies to Present at the 25th Annual BIO-EUROPE® International Partnering Conference
November 04, 2019 08:45 ET
|
AZTherapies, Inc.
BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that its Director of Business Development,...